Merck KGaA (OTCMKTS:MKKGY) Stock Rating Lowered by Zacks Research

Merck KGaA (OTCMKTS:MKKGY) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday, Zacks reports.

Several other equities analysts also recently weighed in on MKKGY. UBS Group downgraded shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. HSBC upgraded shares of Merck KGaA to a “hold” rating in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Merck KGaA Trading Down 0.3%

Shares of OTCMKTS:MKKGY opened at $30.89 on Monday. The stock has a 50 day moving average of $31.51 and a 200 day moving average of $30.23. The company has a market cap of $19.96 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.69, a quick ratio of 1.09 and a debt-to-equity ratio of 0.37. Merck KGaA has a 12-month low of $23.73 and a 12-month high of $34.19.

About Merck KGaA

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. The company operates independently from Merck & Co, Inc, the U.S.-based company that uses the Merck name in the United States and Canada.

Merck KGaA operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, analytical technologies and bioprocessing solutions used by pharmaceutical and biotechnology companies, academic institutions and industrial laboratories.